CD40L (human) (multimeric) (rec.)
| Code | Size | Price |
|---|
| AG-40B-0010-C010 | 10 ug | £300.00 |
Quantity:
| AG-40B-0010-3010 | 3 x 10 ug | £590.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Hamster
Regulatory Status: RUO
Target Species: Human
Shipping:
Blue Ice
Storage:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
MultimericCD40L™; ACRP30headless:CD40L; ACRP30headless:CD154; ACRP30headless:TNFSF5; ADIPOQ-CD40L
Biological Activity:
Induces B cells activation (as demonstrated by dose-dependent upregulation of CD86) (ED50: <1ng/ml). B cell expansion online protocol available.
Concentration:
0.1mg/ml after reconstitution.
EClass:
32160000
Endotoxin:
<0.01EU/µg purified protein (LAL test, Lonza).
Form (Short):
liquid
Formulation:
Lyophilized. Contains PBS
Handling Advice:
After reconstitution, prepare aliquots and store at -20°C.Avoid freeze/thaw cycles.Centrifuge lyophilized vial before opening and reconstitution.PBS containing at least 0.1% BSA should be used for further dilutions.
Long Description:
Protein. Human CD40L (aa 116-261) is fused at the N-terminus to mouse ACRP30headless (aa 18-111) and a FLAG®-tag. Source: CHO cells. Endotoxin content: <0.01EU/µg purified protein (LAL test; Lonza). Lyophilized. Contains PBS Binds to human CD40. Purity: >95% (SDS-PAGE). MultimericCD40L™ is a high activity construct in which two trimeric CD40 ligands are artificially linked via the collagen domain of ACRP30. This construct very effectively simulates the natural membrane-assisted aggregation of CD40L in vivo. It provides a simple and equally potent alternative to combinations. MultimericCD40L™ has shown to suppress alum-induced IL-1beta release and caspase-1 activation in a dose-, CD40- and time dependent manner, without affecting BMDM viability. It also effectively suppressed the inflammasome function triggered by NLRP3 activators. The secretion of caspase-1 independent inflammatory mediators has been shown to be unaltered or even enhanced.
Molecular Weight:
~35-40kDa (SDS-PAGE)
NCBI, Uniprot Number:
P29965
Package Type:
Plastic Vial
Product Description:
MultimericCD40L™ is a high activity construct in which two trimeric CD40 ligands are artificially linked via the collagen domain of ACRP30. This construct very effectively simulates the natural membrane-assisted aggregation of CD40L in vivo. It provides a simple and equally potent alternative to [CD40L+enhancer] combinations. MultimericCD40L™ has shown to suppress alum-induced IL-1beta release and caspase-1 activation in a dose-, CD40- and time dependent manner, without affecting BMDM viability. It also effectively suppressed the inflammasome function triggered by NLRP3 activators. The secretion of caspase-1 independent inflammatory mediators has been shown to be unaltered or even enhanced.
Purity:
>95% (SDS-PAGE)
Sequence:
Human CD40L (aa 116-261) is fused at the N-terminus to mouse ACRP30headless (aa 18-111) and a FLAG®-tag.
Source / Host:
CHO cells
Specificity:
Binds to human CD40.
TAGs:
FLAG
Transportation:
Non-hazardous
UNSPSC Category:
Other Proteins
UNSPSC Number:
12352202
Use & Stability:
Stable for at least 6 months after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C.
References
IgG subclass switch capacity is low in switched and in IgM-only, but high in IgD+IgM+, post-germinal center (CD27+) human B cells: C. Werner-Favre, et al.; Eur. J. Immunol. 31, 243 (2001) | Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex: N. Holler, et al.; Mol. Cell. Biol. 23, 1428 (2003) | Impaired CD40L signaling is a cause of defective IL-12 and TNF-alpha production in Sezary syndrome: circumvention by hexameric soluble CD40L: L.E. French, et al.; Blood 105, 219 (2005) | Cysteine-rich Domain 1 of CD40 Mediates Receptor Self-assembly: C.R. Smulski, et al.; J. Biol. Chem. 288, 10914 (2013) | Sensitive, multiplex and direct quantification of RNA sequences using a modified RASL assay: H.B. Larman, et al.; Nucl. Acids Res. 42, 9146 (2014) | CD4+ T Cell-derived IL-21 and deprivation of CD40 signaling favor the In Vivo development of granzyme B-expressing regulatory B cells in HIV patients: C. Kaltenmeier, et al.; J. Immunol. 194, 3768 (2015) | CRISPR/Cas9 Screens Reveal Multiple Layers of B cell CD40 Regulation: Ch. Jiang, et al.; Cell Rep. 28, 1307 (2019) | Detection of alloreactive T cells from cryopreserved human peripheral blood mononuclear cells: N. Tanimine, et al.; J. Immunol. Meth. 491, 112987 (2021) | Sensitive identification of neoantigens and cognate TCRs in human solid tumors: M. Arnaud, et al.; Nature Biotechnol. ahead of print (2021)
Related Products
| Product Name | Product Code | Supplier | anti-CD40 (mouse), mAb (FGK45) | AG-20B-0036 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| anti-CD40 (mouse), mAb (FGK45) (preservative free) | AG-20B-0036PF | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||